Independent Advisor Alliance Boosts Stock Holdings in Medtronic PLC $MDT

Independent Advisor Alliance lifted its position in Medtronic PLC (NYSE:MDT) by 40.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,103 shares of the medical technology company’s stock after purchasing an additional 19,328 shares during the period. Independent Advisor Alliance’s holdings in Medtronic were worth $6,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. acquired a new position in Medtronic in the 3rd quarter worth about $29,000. Delos Wealth Advisors LLC purchased a new position in Medtronic during the second quarter worth approximately $27,000. Steigerwald Gordon & Koch Inc. acquired a new stake in Medtronic in the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in Medtronic in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $102.96 on Friday. The stock has a market capitalization of $131.99 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a 50-day simple moving average of $99.60 and a 200-day simple moving average of $95.69. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 EPS. Medtronic’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analyst Upgrades and Downgrades

MDT has been the subject of several research analyst reports. Citigroup upped their target price on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Barclays boosted their price target on shares of Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. CICC Research started coverage on shares of Medtronic in a report on Friday. They set an “outperform” rating on the stock. Stifel Nicolaus lifted their target price on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Finally, Robert W. Baird set a $103.00 target price on shares of Medtronic in a research note on Tuesday, December 16th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).